DIGEMID — Discontinuidad de Medicamentos (Peru) (DIGEMID)
DIGEMID — Discontinuidad de Medicamentos (Peru) is the official source of medicine shortage information for Peru (Latin America). Mederti checks its register regularly and links every notice back to the original publication.
- Official register
- serviciosweb-digemid.minsa.gob.pe
- Country
- Peru
- Notices tracked by Mederti
- 1,672
- Last checked
- 10 Sept 2026
Latest notices from DIGEMID
- Mesilato De Bromocriptina — active, medium, since 30 Jun 2027 (source)
- Macitentan; Tadalafil — active, medium, since 11 Apr 2027 (source)
- Clotrimazolo — active, medium, since 31 Mar 2027 (source)
- Clorhidrato De Ambroxol — active, medium, since 5 Mar 2027 (source)
- Nitrofurantoina — active, medium, since 8 Dec 2026 (source)
- Clortalidona — active, medium, since 1 Dec 2026 (source)
- Cloruro Di Calcio + Glicina + Glucosio (Destrosio) Anidro + L-Alanina + L-Arginina + L-Fenilalanina + L-Isoleucina + L-Istidina + L-Leucina + L-Lisina + L-Metionina + L-Prolina + L-Serina + L-Tirosina + L-Treonina + L-Triptofano + L-Valina + Magnesio Solfato + Potassio Cloruro + Sodio Acetato + Sodio Glicerofosfato + Taurina — active, medium, since 1 Dec 2026 (source)
- Citrato De Cafeina — active, medium, since 1 Dec 2026 (source)
- Telmisartan — active, medium, since 27 Nov 2026 (source)
- Cannabidiol — active, medium, since 11 Nov 2026 (source)
- Apixaban — active, medium, since 11 Nov 2026 (source)
- Rivaroxaban — active, medium, since 11 Nov 2026 (source)
- Fosfato Dipotasico — active, medium, since 1 Oct 2026 (source)
- N-L-Alanil-L-Glutamina — active, medium, since 31 Aug 2026 (source)
- Clorhidrato De Ambroxol — active, medium, since 28 Aug 2026 (source)
Every DIGEMID notice, searchable and alertable
Search Peru's full register alongside 50+ other countries — free for individual pharmacists and clinicians.
Create a free accountMederti is not affiliated with or endorsed by DIGEMID — Discontinuidad de Medicamentos (Peru). All notices remain the property of their publisher and are linked to the original source.